Signals
Europe Is Moving to Ban Red Yeast Rice Monacolins. Can Bergamot Fill the Gap?
EU scrutiny of red yeast rice monacolins is accelerating a shift in the cholesterol supplement market toward botanical alternatives, including bergamot-based formulations. A clinically studied bergamot phytocomplex has shown improvements in lipid and metabolic markers in a small randomised trial, but evidence of cardiovascular protection remains absent.
ASCO 2026: Pancreatic cancer gets its precision medicine moment
ASCO 2026: GI cancers are finally moving out of oncology’s blind spot
ASCO 2026: AI is entering cancer care before the rules are ready
ASCO 2026: Are we overtreating cancer?
ASCO 2026: Why oncology is also paying attention to GLP-1 medicines
AI Pathology Moves From Demo to Workflow
AlphaGenome Makes Variant Interpretation Political
The AMR Pipeline Is Too Thin for the Threat Ahead
TB Diagnosis Moves Closer to the Patient
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.